Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01664624 · ClinicalTrials.gov registry record · Phase 1
Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT01664624 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 40 participants.
The verdict
NCT01664624, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effect of roflumilast plus alogliptin on glucagon-like peptide-1 (GLP-1) and glucose levels in patients with type 2 diabetes.
Interventions
- DRUG Roflumilast
- DRUG Exenatide
- DRUG Alogliptin
- DRUG Placebo to roflumilast
- DRUG Placebo to alogliptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2012-07 |
| Est. Completion | 2012-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01664624
The ClinicalTrials.gov registry entry for NCT01664624 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Roflumilast is the first listed.
NCT01664624 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01664624 about?
NCT01664624 is a clinical study titled "Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes". The purpose of this study is to assess the effect of roflumilast plus alogliptin on glucagon-like peptide-1 (GLP-1) and glucose levels in patients with type 2 diabetes.
What is the current status of trial NCT01664624?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2012-07. Estimated completion is 2012-11.
What interventions are being tested in trial NCT01664624?
The interventions under investigation include: Roflumilast (DRUG), Exenatide (DRUG), Alogliptin (DRUG), Placebo to roflumilast (DRUG), Placebo to alogliptin (DRUG).
Who is sponsoring clinical trial NCT01664624?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.